FDA: Los beta-agonista de larga duración no deben usarse solos en el asma

[Pedro del Río Pérez]

Una nota de la FDA sobre los beta-agonistas de larga
duración en el asma:

FDA Announces New Safety Controls for Long-Acting Beta Agonists,
Medications Used to Treat Asthma
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm>

The FDA will now require that the product labels reflect the following:

   - The use of LABAs is contraindicated without the use of an asthma
   controller medication such as inhaled corticosteroid. Single-agent LABAs
   should only be used in combination with an asthma controller medication;
   they should not be used alone;
   - LABAs should only be used long-term in patients whose asthma cannot be
   adequately controlled on asthma controller medications;
   - LABAs should be used for the shortest duration of time required to
   achieve control of asthma symptoms and discontinued, if possible, once
   asthma control is achieved. Patients should then be maintained on an
asthma
   controller medication.
   - Pediatric and adolescent patients who require a LABA in addition to an
   inhaled corticosteroid should use a combination product containing both
an
   inhaled corticosteroid and a LABA to ensure compliance with both
   medications.

Más información en:
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm199565.htm


....................................
Pedro del Río Pérez
León
pedrodelrio en uninet.edu
....................................